UNSPSC 51422212: Triamcinolone acetonide sodium phosphate

This classification denotes a therapeutic glucocorticoid C24H30FO9P.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R2MZ7K74S8, chemically known as pregna-1,4-diene-3,20-dione, 9-fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone, 21-(dihydrogen phosphate), disodium salt, but more generally known as triamcinolone acetonide sodium phosphate, which bears US NIH Compound Identifier 70683053.

Most nations, for tariff and trade purposes, schedule triamcinolone acetonide sodium phosphate under HS 29372200 and SITC 54153. As of Q4 2014, TRIAMCINOLONE ACETONIDE SODIUM PHOSPHATE remains US FDA's Preferred Term for this commodity. SMILES: C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)COP(=O)([O-])[O-])CCC5=CC(=O)C=C[C@@]53C)F)O.[NA+].[NA+].

UNSPSC 51422212 Triamcinolone acetonide sodium phosphate is a Commodity code whose recent state and local activity shows a significant mismatch between the code's nominal pharmaceutical scope and the work actually being solicited. The code nominally describes a specific corticosteroid injectable, but recent opportunities tagged to it involve naloxone procurement and pharmacy benefit program restructuring—products and services unrelated to triamcinolone acetonide sodium phosphate. State and local governments are not currently soliciting triamcinolone acetonide sodium phosphate through formal competitive notices under this code.

The two recent opportunities on record demonstrate the classification problem. Seminole County, Florida released IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through an IFB with a response deadline of July 26, 2023, with quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, requesting vendor information on direct-to-manufacturer prescription programs and pharmacy benefit management capabilities outside traditional pharmacy benefit manager and group purchasing organization channels—a market-intelligence exercise rather than a procurement for a specific drug product. Neither opportunity aligns with procurement of triamcinolone acetonide sodium phosphate. The code shows little relevant recent activity and appears to be tagged inconsistently with actual state and local contracting needs.